A new protocol for high-yield purification of recombinant human CXCL8(3-72)K11R/G31P expressed in Escherichia coli

Protein Expression and Purification

Volumn 61, Issue 1, 2008, Pages 65-72

  Cheng, Hsi Tsung ^a,b   Huang, Kuo Chun ^a   Yu, Hui Yuan ^a   Gao, Kun Jhih ^a   Zhao, Xixing ^c   Li, Fang ^c   Town, Jennifer ^c   Gordon, John R ^c,d   Cheng, Jya Wei ^a,b  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b Pacgen Biopharmaceuticals Corporation   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

Antagonist; CXCL8; Endotoxin; Expression; Lipopolysaccharide; Purification

Indexed keywords

HYBRID PROTEIN; INTERLEUKIN 8;

ARTICLE; CALORIMETRY; CIRCULAR DICHROISM; CYTOLOGY; ESCHERICHIA COLI; GENETICS; HUMAN; ISOLATION AND PURIFICATION; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NUCLEAR MAGNETIC RESONANCE; ULTRACENTRIFUGATION;

CALORIMETRY; CHEMOTAXIS, LEUKOCYTE; CIRCULAR DICHROISM; ESCHERICHIA COLI; HUMANS; INTERLEUKIN-8; NEUTROPHILS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; RECOMBINANT FUSION PROTEINS; ULTRACENTRIFUGATION;

ESCHERICHIA COLI;

EID: 47749148374     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2008.04.007     Document Type: Article

References (26)

1. Godessart N. Chemokine receptors: attractive targets for drug discovery. Ann. N.Y. Acad. Sci. 1051 (2005) 647-657
2. Bizzarri C., Beccari A.R., Bertini R., Cavicchia M.R., Giorgini S., and Allegretti M. ELR+ CXC chemokines and their receptors CXCR1 and CXCR2 as new therapeutic targets. Pharmacol. Ther. 112 (2006) 139-149
3. Busch-Petersen J. Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases. Curr. Top. Med. Chem. 6 (2006) 1345-1352
4. Clore G.M., Appella E., Yamada M., Matsushima K., and Gronenborn A.M. Three-dimensional structure of interleukin 8 in solution. Biochemistry 29 (1990) 1689-1696
5. Baldwin E.T., Weber I.T., St. Charles R., Xuan J.C., Appella E., Yamada M., Matsushima K., Edwards B.F., Clore G.M., and Gronenborn A.M. Crystal structure of interleukin 8 symbiosis of NMR and crystallography. Proc. Natl. Acad. Sci. USA 88 (1991) 502-506
6. Clark-Lewis I., Schumacher C., Baggiolini M., and Moser B. Structure-activity relationships of interleukin-8 determined using chemically synthesized analogs. Critical role of NH2-terminal residues and evidence for uncoupling of neutrophil chemotaxis exocytosis and receptor binding activities. J. Biol. Chem. 266 (1991) 23128-23134
7. Hebert C.A., Vitangcol R.V., and Baker J.B. Scanning mutagenesis of interleukin-8 identifies a cluster of residues required for receptor binding. J. Biol. Chem. 266 (1991) 18989-18994
8. Hammond M.E., Shyamala V., Siani M.A., Gallegos C.A., Feucht P.H., Abbott J., Lapointe G.R., Moghadam M., Khoja H., Zakel J., and Tekamp-Olson P. Receptor recognition and specificity of interleukin-8 is determined by residues that cluster near a surface-accessible hydrophobic pocket. J. Biol. Chem. 271 (1996) 8228-8235
9. Clark-Lewis I., Dewald B., Loetscher M., Moser B., and Baggiolini M. Structural requirements for interleukin-8 function identified by design of analogs and CXC chemokine hybrids. J. Biol. Chem. 269 (1994) 16075-16081
10. Skelton N.J., Quan C., Reilly D., and Lowman H. Structure of a CXC chemokine-receptor fragment in complex with interleukin-8. Structure 7 (1999) 157-168
11. Li F., and Gordon J.R. IL-8(3-73) K11R is a high affinity agonist of the neutrophil CXCR1 and CXCR2. Biochem. Biophys. Res. Commun. 286 (2001) 595-600
12. Li F., Zhang X., and Gordon J.R. CXCL8(3-73)K11R/G31P antagonizes ligand binding to the neutrophil CXCR1 and CXCR2 receptors and cellular responses to CXCL8/IL-8. Biochem. Biophys. Res. Commun. 293 (2002) 939-944
13. X. Zhao, J.R. Town, F. Li, X. Zhang, D. Cockcroft, J.R. Gordon, ELR-CXC chemokine receptor antagonism targets inflammatory responses at multiple levels, submitted for publication.
14. Hou D., Yan Z., Shi J., Han W., and Zhang Y. Expression and one-step ion-exchange purification of (AAR)IL-8 (human IL-8 receptor antagonist). Protein Expr. Purif. 44 (2005) 104-109
15. Salek-Ardakani S., Stuart A.D., Arrand J.E., Lyons S., Arrand J.R., and Mackett M. High level expression and purification of the Epstein-Barr virus encoded cytokine viral interleukin 10 efficient removal of endotoxin. Cytokines 17 (2002) 1-13
16. Burrows S.D., Doyle M.L., Murphy K.P., Franklin S.G., White J.R., Brooks I., McNulty D.E., Scott M.O., Knutson J.R., and Porter D. Determination of the monomer-dimer equilibrium of interleukin-8 reveals it is a monomer at physiological concentrations. Biochemistry 33 (1994) 12741-12745
17. Schletter J., Heine H., Ulmer A.J., and Rietschel E.T. Molecular mechanisms of endotoxin activity. Arch. Microbiol. 164 (1995) 383-389
18. Lang C.H., and Spitzer J.A. Glucose kinetics and development of endotoxin tolerance during long-term continuous endotoxin infusion. Metabolism 36 (1987) 469-474
19. Bito L.Z. Inflammatory effects of endotoxin-like contaminants in commonly used protein preparations. Science 196 (1977) 83-85
20. Fraker D.L., Stovroff M.C., Merino M.J., and Norton J.A. Tolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity. J. Exp. Med. 168 (1988) 95-105
21. Vanhaecke E., De Muynck C., Remon J.P., and Colardyn F. Endotoxin removal by end-line filters. J. Clin. Microbiol. 27 (1989) 2710-2712
22. Liu S., Tobias R., McClure S., Styba G., Shi Q., and Jackowski G. Removal of endotoxin from recombinant protein preparations. Clin. Biochem. 30 (1997) 455-463
23. Aida Y., and Pabst M.J. Removal of endotoxin from protein solutions by phase separation using Triton X-114. J. Immunol. Methods 132 (1990) 191-195
24. Adam O., Vercellone A., Paul F., Monsan P.F., and Puzo G. A nondegradative route for the removal of endotoxin from exopolysaccharides. Anal. Biochem. 225 (1995) 321-327
25. Tzeng S.R., Pai M.T., Lung F.D., Wu C.W., Roller P.P., Lei B., Wei C.J., Tu S.C., Chen S.H., Soong W.J., and Cheng J.W. Stability and peptide binding specificity of Btk SH2 domain: molecular basis for X-linked agammaglobulinemia. Protein Sci. 9 (2000) 2377-2385
26. Fernando H., Chin C., Rosgen J., and Rajarathnam K. Dimer dissociation is essential for interleukin-8 (IL-8) binding to CXCR1 receptor. J. Biol. Chem. 279 (2004) 36175-36178